COMPANY

AusperBio

Profile checked Oct 10, 2026

Keywords: Chronic Hepatitis B AHB-137 AHB-171

Timeline

Sep 1, 2026 Trial start Phase 2: Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions source ↗
Jul 6, 2026 Trial start Phase 1: Study of AHB-171 in Chronic Hepatitis B Participants source ↗
Mar 6, 2026 Trial start 2: Phase 2 Study of AHB-137 in HBeAg Negative Chronic Hepatitis B (CHB) Participants in Asia Pacific Region source ↗
Feb 28, 2023 Trial start Phase 1: A Study Evaluating AHB-137 in Healthy Participants and Participants with Chronic Hepatitis B source ↗

May 11, 2027 (ESTIMATED) · Phase 2 · Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions · NCT07654283
Oct 8, 2027 (ESTIMATED) · Phase 1 · Study of AHB-171 in Chronic Hepatitis B Participants · NCT07617194
Dec 31, 2028 (ESTIMATED) · 2 · Phase 2 Study of AHB-137 in HBeAg Negative Chronic Hepatitis B (CHB) Participants in Asia Pacific Region · NCT07370207

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT07654283	Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions	Phase 2	Recruiting	Sep 1, 2026	May 11, 2027 (estimated)
NCT07370207	Phase 2 Study of AHB-137 in HBeAg Negative Chronic Hepatitis B (CHB) Participants in Asia Pacific Region	2	Recruiting	Mar 6, 2026	Dec 31, 2028 (estimated)
NCT07617194	Study of AHB-171 in Chronic Hepatitis B Participants	Phase 1	Not yet recruiting	Jul 6, 2026	Oct 8, 2027 (estimated)
NCT05717686	A Study Evaluating AHB-137 in Healthy Participants and Participants with Chronic Hepatitis B	Phase 1	Completed	Feb 28, 2023	Jan 7, 2025 (actual)